Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma

12 Jun 2025

Abstract excerpt

ABSTRACT: CD19-directed chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) and recently showed effects in autoimmune diseases, such as systemic lupus erythematosus (SLE). Despite high levels of inflammation, toxicity seemed to differ between patients with SLE and B-NHL. We therefore compared the CAR T-cell kinetics and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biosimilars and Bioanalytical Methods
Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40504989
DOI: 10.1182/blood.2025028375

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 11 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphomaPMID 40504989Read ↗

Overview of Adverse Events Associated With Anti-CD19 Chimeric Antigen Receptor T-Cell TherapySemantic proximity Read ↗

Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational studySemantic proximity Read ↗

Interferon-γ blockade in CAR T-cell therapy–associated macrophage activation syndrome/hemophagocytic lymphohistiocytosisSemantic proximity Read ↗

Prolonged Cytopenia with CAR-T Cell Therapy and Management RecommendationsSemantic proximity Read ↗

Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to managementSemantic proximity Read ↗

Exploring CAR T-Cell Dynamics: Balancing Potent Cytotoxicity and Controlled Inflammation in CAR T-Cells Derived from Systemic Sclerosis and Myositis PatientsSemantic proximity Read ↗

B cells in systemic lupus erythematosusSemantic proximity Read ↗

Lenalidomide enhances CD19 CAR-T cell fitness and target-cell engagement in relapsed/refractory CLLSemantic proximity Read ↗

Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphomaSemantic proximity Read ↗

CD19-directed CAR T-cell therapy for treatment of primary CNS lymphomaSemantic proximity Read ↗

CD19-directed CAR T-cell therapy in B-cell NHLSemantic proximity Read ↗

SLE Antibody-Secreting Cells Are Characterized by Enhanced Peripheral Maturation and Survival ProgramsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.